EGFRvIII TandAbs are specific and highly potent drug candidates for the treatment of a variety of solid tumors
Ellwanger et al.
CIMT 2015
Ellwanger et al.
CIMT 2015
Reusch et al.
MAbs. 2015 May 4; 7(3):584-604. doi: 10.1080/19420862.2015.1029216. [PubMed - in process].
Eissenberg et al.
ASCO 2015
Reusch et al.
ASCO 2015
Reusch et al.
ASCO 2015
Weichel et al.
European Pharmaceutical Review 2015 20(1): 27-32
Rothe et al.
ASH 2014
Reusch et al.
PEGS 2014
Reusch et al.
MAbs. 2014 Mar 26; 6(3).
Reiners et al.
Mol Ther. 2013 Apr; 21(4):895-903. doi: 10.1038/mt.2013.14. Epub 2013 Mar 5./.